Trial intelligence / Profile preview

Carvedilol vs Atenolol in Stable Angina Pectoris

NCT02547597Phase 4

Key facts

Status: Completed
Start: Apr 2011
Primary completion: Aug 2013
Countries: 1
Sponsor: Gachon University Gil Medical Center
Modality: Small Molecules

Drugs: carvedilol
Conditions: stable angina pectoris

Overview

Phase 4, randomised, open-label trial of carvedilol in stable angina pectoris (2 arms), sponsored by Gachon University Gil Medical Center. Primary endpoints: Time to 1-mm ST-segment depression at 25 weeks and Time to onset of angina at 25 weeks. Started Apr 2011; status: completed.

Design

2 arms

Study design: RandomizedOpen-label

Carvedilol Arm
Carvedilol 25 mg twice a day
Atenolol Arm
Atenolol 50 mg twice a day

Endpoints

Primary

Time to 1-mm ST-segment depression25 weeks
Time to onset of angina25 weeks

Secondary

Blood pressure at resting and peak exercise25 weeks
Heart rate at resting and peak exercise25 weeks
Lipid profiles25 weeks
Glucose metabolism25 weeks
Seattle Angina Questionnaire scores25 weeks
Treatment-emergent adverse events25 weeks

Beyond the preview

Go deeper on NCT02547597.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT02547597.